RCC Treatment Strategies in a Favorable-Risk Patient
A Whole New World of RCC: Are You Ready?
Click the "View Activity" button to view this activity.View Activity
CME/CE is no longer available for this activity
• Discuss the major clinical trials that support the use of TKIs and immunotherapy for ccRCC
• Explain considerations for selecting a first-line treatment regimen for a patient with ccRCC, including biomarkers, adverse events, and medical comorbidities
• Apply clinical trial evidence and available recommendations to formulate tailored treatment regimens for advanced RCC
• Describe techniques and strategies for establishing shared decision-making in the selection of treatment for RCC
This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
Questions regarding accreditation can be directed to ContinuingEd@pennstatehealth.psu.edu or 717-531-6483. Refer to course number G6761-22-T.
Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Penn State College of Medicine designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.